Mitochondria-targeted agents: Future perspectives of mitochondrial pharmaceutics in cardiovascular diseases
about
Barth Syndrome: From Mitochondrial Dysfunctions Associated with Aberrant Production of Reactive Oxygen Species to Pluripotent Stem Cell StudiesCrosstalk between mitochondria and peroxisomesThe Role of Cardiolipin in Cardiovascular HealthThe protective effect of lipoic acid on selected cardiovascular diseases caused by age-related oxidative stressTargeting mitochondrial dysfunction in the treatment of heart failure.Mitochondria-Targeted Vitamin E Protects Skin from UVB-Irradiation.Apelin regulates FoxO3 translocation to mediate cardioprotective responses to myocardial injury and obesity.Network analysis of mitonuclear GWAS reveals functional networks and tissue expression profiles of disease-associated genes.Protective effect of mitochondria‑targeted peptide MTP‑131 against oxidative stress‑induced apoptosis in RGC‑5 cells.Mitochondrial involvement in myocyte death and heart failure.Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure.Mitochondria as a target of cardioprotection in models of preconditioning.Magnetomitotransfer: An efficient way for direct mitochondria transfer into cultured human cellsMuscle Weakness in Rheumatoid Arthritis: The Role of Ca2+ and Free Radical Signaling.The Role of Mitochondria in AMD: Current Knowledge and Future Applications.Direct effect of chronic hypoxia in suppressing large conductance Ca(2+)-activated K(+) channel activity in ovine uterine arteries via increasing oxidative stress.Exposure to a 50-Hz magnetic field induced mitochondrial permeability transition through the ROS/GSK-3β signaling pathway.The expression characteristics of mt-ND2 gene in chicken.Mitochondria-Targeted Antioxidant SkQ1 Prevents Anesthesia-Induced Dry Eye Syndrome.The role of mitofilin in left ventricular hypertrophy in hemodialysis patients.Polymer Functionalization of Isolated Mitochondria for Cellular Transplantation and Metabolic Phenotype Alteration.
P2860
Q26772690-5CDA41A5-B442-49F7-9146-B2929841470BQ26775421-2F6EA255-CD3F-47F0-A41C-498002DC5B3EQ26798052-3F409D26-B769-40D1-8839-239740C8AFD8Q26822734-4AE4B811-4EB0-4D8F-8723-CE26065084FCQ30243930-096B01ED-751D-465D-8396-FC1620CE972AQ35921682-2E04A7A8-8588-4D73-8C43-2010DC767C91Q36254873-7D60D9F5-692C-4BAC-9FAA-0F748789F893Q37559800-62408127-8204-4DE2-A191-6C116C441FB1Q37720064-041D5469-405F-4473-A548-2DAF652D1C1AQ38737214-39B7569D-A469-4A53-A362-71863F381F90Q39401767-E51DB56C-D2AB-44F3-BF6E-1E15093770E6Q39449539-68661187-B961-4731-905C-0DB07AE5EB83Q41523614-63EA1AD4-79E0-4CF1-AD78-CBB5B1DDB6A0Q41688477-E711A4F0-313B-42C8-A04D-2A697C9BBD6DQ45975184-7E5603EA-3CE2-4A7D-9B33-996A7C2C7822Q46245171-FEFCF4F8-9798-4626-A348-FBD271EF3299Q46599756-B919BADC-403E-42A0-8A48-AE63DA0C6D1EQ46675663-06581C43-0C5C-4D2F-B7ED-85CA1FF89AE4Q47093888-4E5E0C81-9F9F-4639-80C8-B255ED3D85EFQ52605495-5CE78BC8-206C-4639-A65B-74DF5AF169C1Q52624291-69A19326-BC1C-4B93-B33F-E2EFE493BD48
P2860
Mitochondria-targeted agents: Future perspectives of mitochondrial pharmaceutics in cardiovascular diseases
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mitochondria-targeted agents: ...... ics in cardiovascular diseases
@ast
Mitochondria-targeted agents: ...... ics in cardiovascular diseases
@en
Mitochondria-targeted agents: ...... ics in cardiovascular diseases
@nl
type
label
Mitochondria-targeted agents: ...... ics in cardiovascular diseases
@ast
Mitochondria-targeted agents: ...... ics in cardiovascular diseases
@en
Mitochondria-targeted agents: ...... ics in cardiovascular diseases
@nl
prefLabel
Mitochondria-targeted agents: ...... ics in cardiovascular diseases
@ast
Mitochondria-targeted agents: ...... ics in cardiovascular diseases
@en
Mitochondria-targeted agents: ...... ics in cardiovascular diseases
@nl
P2860
P3181
P356
P1476
Mitochondria-targeted agents: ...... ics in cardiovascular diseases
@en
P2093
Thekkuttuparambil Ananthanarayanan Ajith
P2860
P304
P3181
P356
10.4330/WJC.V6.I10.1091
P407
P577
2014-10-26T00:00:00Z